Akebia Therapeutics
AKBA
164 hedge funds and large institutions have $263M invested in Akebia Therapeutics in 2020 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 68 increasing their positions, 43 reducing their positions, and 53 closing their positions.
147% more call options, than puts
Call options by funds: $5.32M | Put options by funds: $2.15M
58% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 43
7.94% less ownership
Funds ownership: 79% → 71.06% (-7.9%)
13% less funds holding
Funds holding: 189 → 164 (-25)
45% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 53
83% less capital invested
Capital invested by funds: $1.52B → $263M (-$1.25B)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$90.6M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$64.3M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$42.3M |
| 4 |
Millennium Management
New York
|
+$19.4M |
| 5 |
Morgan Stanley
New York
|
+$8.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
-$204M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$95.5M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$47.7M |
| 4 |
ClearBridge Investments
New York
|
-$20.7M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$16.3M |
AKBA Hedge Fund Activity: Q3 2020 in Review
164 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2020, worth a combined $263M — down 83% from $1.52B a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of AKBA and 29 opened new positions — a net loss of 24 holders — while 43 trimmed existing stakes and 68 added.
The largest buyer was State Street, adding an estimated $90.6M. The largest seller was Baupost Group, exiting entirely with an estimated $204M sold.
- 164 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2020, down from 189 in Q2 2020.
- Funds reported $263M of Akebia Therapeutics stock for Q3 2020, down 83% quarter-over-quarter.
- 29 funds opened new Akebia Therapeutics positions in Q3 2020 and 53 closed out, a net change of -24 holders.
- The largest Akebia Therapeutics buyer in Q3 2020 was State Street, an estimated $90.6M added.
- The largest Akebia Therapeutics seller in Q3 2020 was Baupost Group, an estimated $204M sold.
Based on aggregated 13F filings for Q3 2020.